Milestone Pharmaceuticals annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Milestone Pharmaceuticals Debt-to-Equity Ratio Growth & History (MIST)
Milestone Pharmaceuticals's debt-to-equity ratio was 1.40 for fiscal 2025.
View full Milestone Pharmaceuticals company overviewMilestone Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.40 | −2.77 | −66.47% |
| 2024 | 2024-12-31 | 4.17 | 1.08 | +35.01% |
| 2023 | 2023-12-31 | 3.09 | 3.05 | +8122.72% |
| 2022 | 2022-12-31 | 0.04 | 0.03 | +515.36% |
| 2021 | 2021-12-31 | 0.01 | −0.00 | −7.30% |
| 2020 | 2020-12-31 | 0.01 | 0.00 | +47.15% |
| 2019 | 2019-12-31 | 0.00 | — | — |
Milestone Pharmaceuticals quarterly debt-to-equity ratio
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.30 | — | — |
| Q1 2026 | 2026-03-31 | 1.64 | — | — |
| Q4 2025 | 2025-12-31 | 1.40 | −2.77 | −66.47% |
| Q3 2025 | 2025-09-30 | 2.79 | 0.54 | +24.04% |
| Q4 2024 | 2024-12-31 | 4.17 | 1.08 | +35.01% |
| Q3 2024 | 2024-09-30 | 2.25 | 0.46 | +25.66% |
| Q2 2024 | 2024-06-30 | 1.67 | 0.42 | +33.72% |
| Q1 2024 | 2024-03-31 | 1.32 | 0.39 | +42.76% |
| Q4 2023 | 2023-12-31 | 3.09 | 3.05 | +8122.72% |
| Q3 2023 | 2023-09-30 | 1.79 | 1.76 | +5255.69% |
| Q2 2023 | 2023-06-30 | 1.25 | 1.24 | +19416.25% |
| Q1 2023 | 2023-03-31 | 0.92 | 0.92 | +14610.63% |
| Q4 2022 | 2022-12-31 | 0.04 | 0.03 | +515.36% |
| Q3 2022 | 2022-09-30 | 0.03 | 0.03 | +456.01% |
| Q2 2022 | 2022-06-30 | 0.01 | 0.00 | +7.07% |
| Q1 2022 | 2022-03-31 | 0.01 | −0.00 | −6.81% |
| Q4 2021 | 2021-12-31 | 0.01 | −0.00 | −7.30% |
| Q3 2021 | 2021-09-30 | 0.01 | −0.00 | −35.46% |
| Q2 2021 | 2021-06-30 | 0.01 | 0.00 | +81.52% |
| Q1 2021 | 2021-03-31 | 0.01 | 0.00 | +89.13% |
| Q4 2020 | 2020-12-31 | 0.01 | 0.00 | +47.15% |
| Q3 2020 | 2020-09-30 | 0.01 | 0.00 | +112.61% |
| Q2 2020 | 2020-06-30 | 0.00 | 0.00 | +102.18% |
| Q1 2020 | 2020-03-31 | 0.00 | −0.00 | −4.21% |
| Q4 2019 | 2019-12-31 | 0.00 | — | — |
| Q3 2019 | 2019-09-30 | 0.00 | — | — |
| Q2 2019 | 2019-06-30 | 0.00 | — | — |
| Q1 2019 | 2019-03-31 | 0.00 | — | — |
Milestone Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Milestone Pharmaceuticals's debt-to-equity ratio increased from 0.01 to 1.40, a change of 1.39. The latest reported quarter, Q2 2026, shows 3.30.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Milestone Pharmaceuticals source filings ↗